Our Company Overview Investor Relations CareersPharma ServicesNeoGenomics offers lab services for oncology clinical trialsLearn moreCOVID-19Precision Medicine during this CrisisNeoGenomics and other organizations in the healthcare community unite to form COVID-19 testing industry consortium.Click here to viewLatest Presented: July 21, 2021 Source: Webinar Gastrointestinal Tract Tumor Board Learn More Presented: June 16, 2021 Source: Webinar Gastrointestinal Tract Tumor Board Learn More Presented: June 9, 2021 Source: Webinar Breast Cancer Tumor Board NeoGenomics is proud to offer our Molecular Tumor Boards covering relevant topics in cancer care.… Learn More Presented: June 2, 2021 Source: Webinar Lung Cancer Tumor Board NeoGenomics is proud to offer our Molecular Tumor Boards covering relevant topics in cancer care.… Learn More Presented: May 26, 2021 Source: Webinar Characterizing NSCLC tumor microenvironment using the integrated MultiOmyx-RNAscope assay Subject: Co-detection of a tumor-infiltrating lymphocyte immunofluorescence (IF) panel and… Learn More New Tests Image Available: May 24, 2021 Methodology: Immunohistochemistry (IHC) PD-L1 LDT Programmed cell death ligand 1 (PD-L1) is a transmembrane protein involved in cellular and humoral… Learn More Image Available: May 24, 2021 Methodology: FISH Anaplastic Large Cell Lymphoma FISH Panel Probes: ALK (2p23) | TP63 (3q28) | TBL1XR1/TP63 [inv(3)(q26q28)] | DUSP22-IRF4 (6p25.3) Probes may… Learn More Image Available: May 24, 2021 Methodology: FISH TFE3 Rearrangement Probe(s): TFE3 (Xp11.2) Disease(s): Renal cell carcinoma (RCC), alveolar soft part sarcoma (ASPS) Learn More Image Available: May 24, 2021 Methodology: FISH USP6 Rearrangement Probe(s): USP6 (17p13.2) Disease(s): Nodular fasciitis, aneurysmal bone cysts Learn More Image Available: April 23, 2021 Methodology: Molecular KRAS (G12C) Mutation Analysis for NSCLC Bi-directional sequencing of exons 2, 3, and 4 of the KRAS (includes G12C mutation) gene including… Learn More
